Literature DB >> 12392883

Is creatine kinase a target for AMP-activated protein kinase in the heart?

Joanne S Ingwall1.   

Abstract

By phosphorylating target proteins, AMP-activated protein kinase (AMPK) inhibits ATP-utilizing proteins and activates ATP-synthesizing proteins, thereby increasing ATP synthesis under conditions such as hypoxia and ischemia. It has been proposed that AMPK also phosphorylates and inhibits creatine kinase (CK), the enzyme which catalyzes the reversible transfer of a phosphoryl group between creatine and ADP. Here, we examine the hypothesis that AMPK inactivates CK activity under three conditions where [AMP] and AMP-dependent AMPK velocity increase: increased workload both in the isolated rat heart and in the living rat, hypoxia in the living rat heart and low-flow ischemia in the isolated red blood cell perfused rat heart. For the experiments varying workload in the isolated rat heart (both ejecting and isovolumic models), we also changed oxidizable substrate available to the isolated heart in order to vary the [AMP]/[ATP]. CK reaction velocity in the intact rat heart was directly measured using (31)P magnetization transfer. The metabolically active AMP and ATP pools were determined from (31)P NMR measurements and we calculate AMP-dependent AMPK velocity from the Michaelis-Menten relationship. We found that under normoxic conditions where [AMP] and AMPK velocity increase, the linear relationship between CK and AMPK velocities is positive, not inverse. Under conditions of low pO(2) (hypoxia and low-flow ischemia), CK velocity fell 2-4-fold while the increase in AMP-activated AMPK activity was modest. This analysis illustrates the complex nature of AMPK regulation in the heart.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12392883     DOI: 10.1006/jmcc.2002.2062

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  13 in total

1.  Regulation of tail muscle arginine kinase by reversible phosphorylation in an anoxia-tolerant crayfish.

Authors:  Neal J Dawson; Kenneth B Storey
Journal:  J Comp Physiol B       Date:  2011-04-26       Impact factor: 2.200

2.  Rise above: muscle ring-finger-1 (MURF1) regulation of cardiomyocyte size and energy metabolism.

Authors:  Cam Patterson; Monte S Willis; Andrea Portbury
Journal:  Trans Am Clin Climatol Assoc       Date:  2011

3.  Diabetic cardiomyopathy--to take a long story serious.

Authors:  Bernd Stratmann; Thomas Gawlowski; Diethelm Tschoepe
Journal:  Herz       Date:  2010-05       Impact factor: 1.443

Review 4.  The Role of AMP-activated protein kinase in fuel selection by the stressed heart.

Authors:  Raymond Russell
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

5.  Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo.

Authors:  Monte S Willis; Jonathan C Schisler; Luge Li; Jessica E Rodríguez; Eleanor G Hilliard; Peter C Charles; Cam Patterson
Journal:  Circ Res       Date:  2009-06-04       Impact factor: 17.367

Review 6.  The ABC transporter structure and mechanism: perspectives on recent research.

Authors:  P M Jones; A M George
Journal:  Cell Mol Life Sci       Date:  2004-03       Impact factor: 9.261

7.  Creatine kinase is an alpha myosin heavy chain 3'UTR mRNA binding protein.

Authors:  Marina Vracar-Grabar; Brenda Russell
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

8.  Heart in diabetes: not only a macrovascular disease.

Authors:  Bernd Stratmann; Diethelm Tschoepe
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

Review 9.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

10.  Phosphocreatine interacts with phospholipids, affects membrane properties and exerts membrane-protective effects.

Authors:  Malgorzata Tokarska-Schlattner; Raquel F Epand; Flurina Meiler; Giorgia Zandomeneghi; Dietbert Neumann; Hans R Widmer; Beat H Meier; Richard M Epand; Valdur Saks; Theo Wallimann; Uwe Schlattner
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.